Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors

NCT02207348 · Completed

Last updated 2026-05-28

This clinical trial is testing whether a single dose of the diabetes and obesity medication liraglutide, given by injection with two different pen devices, produces similar levels of the drug in the blood.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 24 people

Who can join Ages 18–60 · all sexes

Timeline Started 2014-08 · est. completion 2014-09

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT02207348 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is to investigate bioequivalence between single-dose liraglutide administered subcutaneously with two different pen-injectors.

Treatments tested

liraglutide Drug

Each subject will receive two single doses of 0.6 mg liraglutide (one with each of the two pen-injectors)

Main thing measured	Area under the liraglutide plasma concentration time curve from 0 to last quantifiable observation (tz) after single dose
Sponsor	Novo Nordisk A/S
Conditions studied	Metabolism and Nutrition Disorder, Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02207348 ↗